We are monitoring the impact of COVID-19 on Europe Active Pharmaceutical Ingredients Market Get in touch with us for detailed analysis Know More
Pulished Date June, 2021
ID: 11676
Share on
Share on

Europe Active Pharmaceutical Ingredients Market Research Report – Segmented By Type of Manufacturing Process, Type of Synthesis, API Formulation, Application, Molecules and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of EU) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: June, 2021
ID: 11676
Pages: 110

Europe Active Pharmaceutical Ingredients Market Size (2021 to 2026)

The size of the Europe Active Pharmaceutical Ingredients Market was valued at USD 48.64 billion in 2020, growing at a CAGR of 8.02% from 2021 to 2026.

The European active pharmaceutical ingredients market is primarily driven by chronic diseases, increasing research and development activities on pharmaceutical ingredients, and advancing biopharmaceuticals in Europe. The increasing geriatric population is more prone to cardiovascular diseases, diabetes, arthritis, asthma, and other chronic obstructive pulmonary diseases. Over the years, these chronic disorders have increased in the geriatric population in the developed countries such as UK, Germany, France, and Italy. In addition, changes in lifestyles and dietary habits brought on by urban development are likely to impact market development. Increasing cardiovascular disorders, cancer, and advancing the manufacturing of active pharmaceutical Ingredients in Europe is expected to augment the European API market growth.

Furthermore, a loss of physiological functions increases the chance of developing diseases such as CVD and diabetes; therefore, the Antibody Drug Conjugates usually utilize APIs in their composition (ADCs). However, market growth is being driven by changes in geopolitical situations. The favorable reimbursement policies for developing active pharmaceutical ingredients and advancing healthcare infrastructure drive the market in the European countries. Considering ADCs are important and successful cancer therapeutic modalities utilized in combination with clinically active medicines and monoclonal antibodies, the development of cancer-specific APIs is projected to boost the API market even more. Moreover, initiatives, increasing investments, and funding by the government and private organizations encourage market growth. 

However, a lack of understanding of using active substances in the correct dosage restricts the European active pharmaceutical ingredients market growth. The most problematic aspect of market demand is the government's strict laws and regulations for pharmaceutical enterprises. In addition, the use of costly and unusual building blocks and raw materials in API chemical synthesis drives up API production costs further. However, the development of these APIs requires substantial investments, which are unaffordable in underdeveloped nations. The high manufacturing cost of APIs and unfavorable drug pricing policies in underdeveloped countries are likely to impede market growth.

Impact of COVID-19 on Europe Active Pharmaceutical Ingredients Market:

The emergence of covid-19 has impacted market growth. The supply chain had been disrupted. As a result, the European market was negatively impacted. Owing to the rapid disease transmission, the nationwide lockdown has been imposed. Major pharmaceutical companies and biopharmaceutical companies, and start-ups have been coming forward to develop a vaccine for the covid-19.  However, drug makers are conducting research and development activities on drug manufacturing, focussing on the rapid patient population. Also, government initiatives for the eradicating the disease, making investments on pharmaceutical drug development institutions. However, the surge in chronic diseases across Europe is estimated to create demand for the market and most likely to have significant growth in the coming years.

This research report on the European active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.

By Type of Manufacturing Process:

  • Captive Manufacturing
  • Contract Manufacturing

By Type of Synthesis:

  • Synthetic
  • Biotech

By API Formulation:

  • Generic API
  • Innovative API

By Application:

  • Cardiovascular Diseases
  • Oncology
  • Neurological Disorders
  • Orthopedic Disorders
  • Respiratory
  • Gastrointestinal Disorders
  • Urology
  • Others

By Molecule:

  • Large Molecule
  • Small Molecule

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of EU

Geographically, the European API market accounted for a significant share in the global active pharmaceutical ingredients market in 2020. The market growth is driven by growing government focus on generic drugs and technological advancements in the manufacturing process of active pharmaceutical ingredients. Also, the increasing prevalence of various chronic disorders and rising demand for active pharmaceutical ingredients market is propelling the market in Europe. The presence of developed economies such as the UK, Germany, France, and Spain increase the regional market. In addition, collaborations and acquisitions expand the regional market growth. The UK is expected to contribute a significant share of active pharmaceutical ingredients to the growth of the European regional market. Advancing healthcare infrastructure and the adoption of technological advancements in API are driving the market. In addition, the launch of drugs and biological products increases market growth. Germany is a promising country in Europe, having a significant share in active pharmaceutical ingredients during the forecast period. Research and development activities conducted on API are showing market growth.

KEY MARKET PLAYERS:

AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, GlaxoSmithKline plc, Lonza Group, Lupin Limited, Merck & Co., Inc., Mylan NV, Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd are a few of the notable companies in the European active pharmaceutical ingredients market.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Type of Manufacturing Process
      1. Captive Manufacturing
      2. Contract Manufacturing
      3. Y-o-Y Growth Analysis, By Manufacturing Process
      4. Market Attractiveness Analysis, By Manufacturing Process
      5. Market Share Analysis, By Manufacturing Process
    2. By Type of Synthesis
      1. Synthetic
      2. Biotech
      3. Y-o-Y Growth Analysis, By Type of Synthesis
      4. Market Attractiveness Analysis, By Type of Synthesis
      5. Market Share Analysis, By Type of Synthesis
    3. By API Formulation
      1. Generic API
      2. Innovative API
      3. Y-o-Y Growth Analysis, By API Formulation
      4. Market Attractiveness Analysis, By API Formulation
      5. Market Share Analysis, By API Formulation
    4. By Application
      1. Cardiovascular Diseases
      2. Oncology
      3. Neurological Disorders
      4. Orthopedic Disorders
      5. Respiratory
      6. Gastrointestinal Disorders
      7. Urology
      8. Others
      9. Y-o-Y Growth Analysis, By Application
      10.  Market Attractiveness Analysis, By Application
      11.  Market Share Analysis, By Application
    5. By Molecule
      1. Large Molecule
      2. Small Molecule
      3. Y-o-Y Growth Analysis, By Molecule
      4. Market Attractiveness Analysis, By Molecule
      5. Market Share Analysis, By Molecule
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Europe
      1. Introduction
      2. UK
      3. France
      4. Spain
      5. Germany
      6. Italy
      7. Russia
      8. Sweden
      9. Denmark
      10. Switzerland
      11. Netherlands
      12. Turkey
      13. Czech Republic
      14. Rest of EU
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Sanofi
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. Bayer AG
    3. Pfizer Inc.
    4. F. Hoffmann-La Roche AG
    5. Abbott Laboratories
    6. Merck & Co., Inc.
    7. Boehringer Ingelheim GmbH
    8. Glaxosmithkline Plc (GSK)
    9. Novartis AG
    10. Eli Lilly and Company
    11. Teva Pharmaceutical Industries Ltd
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of type of manufacturing process, type of synthesis, api formulation, application, molecules along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market, which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Europe Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  2. Europe Captive Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Contract Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  5. Europe Synthetic Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Biotech Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  8. Europe Generic API Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Innovative API Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  11. Europe Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Million)
  12. Europe Oncology Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Orthopaedic Disorders Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Respiratory Market, By Region, From 2021 to 2026 (USD Million)
  16. Europe Gastrointestinal Disorders Market, By Region, From 2021 to 2026 (USD Million)
  17. Europe Urology Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  20. Europe Large Molecule Market, By Region, From 2021 to 2026 (USD Million)
  21. Europe Small Molecule Market, By Region, From 2021 to 2026 (USD Million)
  22. U.K. Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  23. U.K. Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  24. U.K. Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  25. U.K. Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  26. U.K. Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  27. Germany Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  28. Germany Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  29. Germany Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  30. Germany Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  31. Germany Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  32. France Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  33. France Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  34. France Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  35. France Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  36. France Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  37. Italy Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  38. Italy Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  39. Italy Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  40. Italy Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  41. Italy Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  42. Spain Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  43. Spain Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  44. Spain Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  45. Spain Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  46. Spain Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample